Prognostic role of SIRT1 in hepatocellular carcinoma

Journal of the College of Physicians and Surgeons Pakistan

Volumn 24, Issue 11, 2014, Pages 849-854

  Song, Shijun ^a   Luo, Min ^a   Song, Yan ^a   Liu, Tianji ^a   Zhang, Haishan ^a   Xie, Zhongshi ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Immunohistochemistry; P53; SIRT1; YAP2

Indexed keywords

ONCOPROTEIN; PROTEIN P53; PROTEIN YAP2; SIRTUIN 1; UNCLASSIFIED DRUG; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; ADOLESCENT; CHINA; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; SURVIVAL; YOUNG ADULT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CHINA; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHOPROTEINS; RETROSPECTIVE STUDIES; SIRTUIN 1; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84915827938     PISSN: 1022386X     EISSN: 16817168     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Choi HN, Bae JS, Jamiyandorj U, Noh SJ, Park HS, Jang KY, et al. Expression and role of SIRT1 in hepatocellular carcinoma. Oncol Rep 2011; 26:503-10.
2. Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan F, et al. SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene 2014; 33:1468-74.
3. Li K, Luo J. The role of SIRT1 in tumorigenesis. N A J Med Sci 2011; 4:104-6.
4. Jang KY, Noh SJ, Lehwald N, Tao GZ, Bellovin DI, Park HS, et al. SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One 2012; 7:e45119.
5. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 2009; 41:366-71.
6. Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 2011; 42:204-13.
7. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008; 14: 312-23.
8. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 2009; 69: 1702-5.
9. Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 2008; 32: 1523-31.
10. Feng AN, Zhang LH, Fan XS, Huang Q, Ye Q, Wu HY, et al. Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance. Int J Surg Pathol 2011; 19: 743-50.
11. Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol 2012; 19:2011-9.
12. Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, et al. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene 2014; 33:2557-67.
13. Noguchi A, Li X, Kubota A, Kikuchi K, Kameda Y, Zheng H, et al. SIRT1 expression is associated with good prognosis for head and neck squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 115:385-92.
14. Fleming Id CJ, Henson De, Hutter Rvp, Kennedy Bj, Murphy Gp. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven 1997:98-126.
15. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, et al. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 2009; 284:18210-7.
16. Chen J, Zhang B, Wong N, Lo AW, To KF, Chan AW, et al. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res 2011; 71:4138-49.
17. Portmann S, Fahrner R, Lechleiter A, Keogh A, Overney S, Laemmle A, et al. Antitumor effect of SIRT1 inhibition in human HCC tumor models in vitro and in vivo. Mol Cancer Ther 2013; 12:499-508.
18. Stunkel W, Peh BK, Tan YC, Nayagam VM, Wang X, Salto- Tellez M, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2007; 2:1360-8.
19. Byles V, Chmilewski LK, Wang J, Zhu L, Forman LW, Faller DV, et al. Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci 2010; 6:599-612.
20. Jin Q, Yan T, Ge X, Sun C, Shi X, Zhai Q. Cytoplasm-localized SIRT1 enhances apoptosis. J Cell Physiol 2007; 213:88-97.
21. Ohsawa S, Miura M. Caspase-mediated changes in Sir2alpha during apoptosis. FEBS Lett 2006; 580:5875-9.
22. Yi J, Luo J. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta 2010; 1804:1684-9.
23. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, et al. Yesassociated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; 115:4576-85.
24. Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem 2007; 282:6823-32.